Among the biological agents currently available for asthma treatment, some of the most used are mepolizumab, reslizumab, and benralizumab, which interfere with the functions of IL-5 and, in the case of the latter, has cytotoxic activity against cells that express the IL-5 receptor; dupilumab, that blocks IL-4 receptor α (187–189); omalizumab, that leads to a reduce binding of IgE to its receptor as well as downregulates the FcεRI expression (190); and tezepelumab, that blocks TSLP and probed useful in cases of type-2 low asthma (191). Here, IL5 is linked to asthma.